Emerging theragnostic radionuclide applications for hepatocellular carcinoma

Area of Science:

• Oncology
• Nuclear Medicine
• Personalized Medicine

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health challenge.
• Current treatment strategies require enhanced precision and personalization.

Purpose of the Study:

• To explore the role and potential of theragnostics in Hepatocellular Carcinoma (HCC) management.
• To highlight how integrated diagnostic and therapeutic approaches can personalize HCC care.

Main Methods:

• Utilizing advanced imaging techniques like Positron Emission Tomography (PET) and Single Photon Emission Tomography (SPECT) with radiolabeled tracers.
• Employing molecular and genetic tests to identify specific HCC biomarkers.
• Investigating radioembolization as a therapeutic modality.

Main Results:

• Theragnostics enables precise diagnosis and characterization of HCC, including size, location, and spread.
• Biomarker identification guides personalized treatment decisions.
• Post-treatment assessment of dosimetry and localization optimizes future therapeutic strategies.

Conclusions:

• Theragnostics represents a promising emerging field for improving HCC diagnosis and treatment.
• The integration of diagnostic and therapeutic modalities offers a pathway to personalized HCC medicine.
• This approach has the potential to significantly improve patient outcomes in HCC management.